CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model

Cancer Gene Therapy

Volumn 23, Issue 6, 2016, Pages 162-167

  Nguyen Hoai, T ^a,b   Pham Duc, M ^a,b   Gries, M ^a,b   Dorken B ^a,b   Pezzutto, A ^a,b   Westermann, J ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLOGICAL ADJUVANT; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PLASMID DNA; SECONDARY LYMPHOID TISSUE CHEMOKINE;

3T3 CELL LINE; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG POTENTIATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNOPOTENTIATION; INNATE IMMUNITY; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; CELL LINE; DISEASE MODEL; GENE EXPRESSION; GENE ORDER; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PLASMID;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL LINE; CHEMOKINE CCL4; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE ORDER; HUMANS; IMMUNIZATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PLASMIDS; RECEPTOR, ERBB-2; TUMOR BURDEN; VACCINES, DNA;

EID: 84964055231     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.9     Document Type: Article

References (49)

1. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Annu Rev Immunol 2000; 18: 927-974.
2. Choo AY, Choo DK, Kim JJ, Weiner DB. DNA vaccination in immunotherapy of cancer. Cancer Res 2005; 123: 137-156.
3. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004; 114: 1241-1244.
4. Rice J, Ottensmeier CH, Stevenson F. DNA vaccines: precision tools for activating Effective immunity against cancer. Nat Rev Immunol 2008; 8: 108-120.
5. Prud'homme G. DNA vaccination against tumors. J Gene Med 2005; 7: 3-17.
6. Iezzi M, Quaglino E, Amici A, Lollini P, Forni G, Cavallo F. DNA vaccination against oncoantigens.A promise. OncoImmunology 2012; 1: 316-325.
7. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, Van D., Littel-Vanden Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003; 21: 649-658.
8. Scheerlinck JP. Genetic adjuvants for DNA vaccines. Vaccine 2001; 19: 2647-2656.
9. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007; 25: 3731-3741.
10. Stewart TJ, Smyth MJ. Chemokine-chemokine receptors in cancer immunotherapy. Immunother 2009; 1: 109-127.
11. Bobanga ID, Petrosiute, Huang AY. Chemokines as cancer vaccine adjuvants. Vaccines 2013; 1: 444-462.
12. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007; 25: 787-920.
13. Homey B, Müller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev immunol 2002; 2: 175-184.
14. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008; 9: 970-980.
15. Viola A, Contento RL, Molon B. T cells and their partners: the chemokine dating agency. Trends Immunol 2006; 27: 421-427.
16. Eo SK, Lee S, Kumaraguru U, Rouse BT. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine 2001; 19: 4685-4693.
17. Toka FN, Gierynska M, Rouse BT. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J Virol 2003; 77: 12742-12752.
18. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH et al. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000; 164: 4025-4031.
19. Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Atianzar K et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gammadependent antitumor responses in a lung cancer model. J Immunol 2003; 171: 6457-6465.
20. Hillinger S, Yang SC, Batra RK, Striete RM, Weder W, Dubinett SM et al. CCL19 reduces tumour burden in a model of advanced lung cancer. Br J Cancer 2006; 94: 1029-1034.
21. Westermann J, Nguyen-Hoai T, Baldenhofer G, Höpken UE, Lipp M, Dörken B et al. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther 2007; 14: 523-532.
22. Nguyen-Hoai T, Baldenhofer G, Ahmed MS, Pham-Duc M, Gries M, Lipp M et al. CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model. J Gene Med 2012; 14: 128-137.
23. Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed MS, Pham-Duc M, Lipp M, Dörken B et al. CCL21 (SLC) improves tumor by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Ther 2012; 19: 69-76.
24. Sharma S, Stolin M, Luo J, Strieter RM, Burdick M, Zhu LX et al. Secondary Lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000; 164: 4558-4563.
25. Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M et al. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2001; 61: 6406-6412.
26. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Cancer Res 2004; 10: 2891-2901.
27. Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2006; 66: 3205-3213.
28. Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C et al. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology 2006; 117: 419-430.
29. Lillard JW, Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR. MIP-1a and MIP-1b differentially mediate mucosal and systemic adaptive immunity. Blood 2003; 101: 807-814.
30. Nguyen-Hoai T, Hohn O, Vu MD, Baldenhofer G, Sayed Ahmed MS, Dörken B et al. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC. Cancer Gene Ther 2012; 19: 880-887.
31. Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wie WZ et al. CD4+T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004; 109: 259-264.
32. Nagata Y, Furugen R, Hiasa A. Peptides derived from a wild-type murine protooncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336-1343.
33. Correa I, Plunkett T. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res 2001; 3: 399-403.
34. Vertuani S, Sette A, Sidney J. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol 2004; 172: 3501-3508.
35. Chen D, Murphy B, Sung R, Bromberg JS. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Ther 2003; 10: 991-998.
36. Novak L, Igoucheva O, Cho S, Alexeev V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther 2007; 6: 1755-1764.
37. Thanarajasingam U, Sanz L, Diaz R, Qiao J, Sanchez-Perez L, Kottke T et al. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 2007; 67: 300-308.
38. Song R, Liu S, Leong KW. Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines. Mol Ther 2007; 15: 1007-1015.
39. Song JH, Kim JI, Kwon HJ, Shim DH, Parajuli N, Cuburu N et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol 2009; 182: 6851-6860.
40. Song S, Liu C, Wang J, Zhang Y, You H, Wang Y et al. Vaccination with combination of Flt3L and RANTES in a DNA prime-protein boost regimen elicits strong cell mediated immunity and antitumor effect. Vaccine 2009; 27: 1111-1118.
41. Rainone V, Dubois G, Temchura V, Uberla K, Clivio A, Nebuloni M et al. CCL28 Induces Mucosal Homing of HIV-1-Specific IgA-Secreting Plasma Cells in Mice Immunized with HIV-1 Virus-Like Particles. PLoS One 2011; 6: e26979.
42. Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer V et al. A Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One 2011; 6: e18758.
43. Franciszkiewicz K, Boissonnas A, Boutet M, Combadiere C, Mami-Chouai F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012; 72: 6325-6332.
44. Igoucheva O, Jonas R, Alexeev V. Chemokine-enhanced DNA vaccination in cancer immunotherapy. Oncoimmunology 2013; 2: e26092.
45. Yan YH, Qi SC, Su LK, Xu QA, Fan MW. Co-delivery of ccl19 gene enhances anticaries DNA vaccine pCIA-P immunogenicity in mice by increasing dendritic cell migration to secondary lymphoid tissues. Acta Pharmacol Sin 2013; 34: 432-440.
46. Hartoonian C, Sepehrizadeh Z, Tabatabai Yazdi M, Jang YS, Langroudi L, Amir Kalvanagh P et al. Enhancement of immune responses by co-delivery of CCL19/MIP-3beta chemokine plasmid with HCV core DNA/protein immunization. Hepat Mon 2014; 14: e14611.
47. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003; 111: 1161-1170.
48. Bachmann MF, Kopf M, Marsland BJ. Chemokines: more than just road signs. Nat Rev Immunol 2006; 6: 159-164.
49. Wuest TR, Carr DJ. The role of chemokines during herpes simplex virus-1 infection. Front Biosci 2008; 13: 4862-4872.